Purdue Abuse Study May Create Ongoing Challenge For Generic Entry
This article was originally published in The Pink Sheet Daily
Executive Summary
OxyContin’s three-year data exclusivity for study of intranasal liking might be just the beginning of labeling hurdles for ANDAs.